Silicon Valley Bank Report: Women Health Funding Fell to 2 Billion in 2025
Quick answer: Silicon Valley Bank found that venture funding for women health companies fell from 3.2 billion dollars in 2024 to around 2 billion in 2025, while the share of healthcare deals involving these companies dropped from 7.4 percent to 5.7 percent. But the same report counts 14 women health startups going public in 2025 and unicorns like Flo Health, Midi Health and Maven. Money is not leaving this space. It is getting pickier about what it funds.
This article is part of the AlphaMa guide to the mental load.
If you have ever waited for an app that actually understands what motherhood demands, the newest funding data matters more than it looks. Silicon Valley Bank, the division of First Citizens Bank that tracks startup funding, released a report showing venture investment in women health companies fell from 3.2 billion dollars in 2024 to around 2 billion in 2025. Biopharma startups in the category were hit hardest, with funding plunging from 1.3 billion dollars to 610 million.
The immediate reaction in your feed was probably some version of "of course." Another cycle where women health gets treated like a niche. But the fuller picture in the SVB report is stranger and more interesting than a simple retreat, and it says a lot about which parts of your life become products and which stay invisible.
Why Traditional Methods Fail
The usual story about underinvestment in women health goes like this: research gaps make the category risky, so investors shy away, so the gaps never close. That story is still true. Douglas Tsao, a senior analyst at H.C. Wainwright, told BioPharma Dive that women health "has been, to some extent, out of favor with traditional biotech investors," and that some recent drugs tailored to women have not been commercially successful. Astellas launched Veozah, a non-hormonal menopause therapy, in 2023, and it struggled with demand and reimbursement before sales reached about 300 million dollars last year.
But the SVB report points at something newer. Megan Scheffel, head of life sciences and healthcare for SVB, describes a "reset" in healthcare investing as a whole: investors are backing more established companies that look like surer bets, and founders now need what she calls "tangible early traction" to raise even a seed round. Progress that used to be the province of a Series A is now required to raise a Seed round.
Layer on top of that the AI boom. Payal Divakaran of .406 Ventures put it bluntly in the report: AI startups are "sucking up a lot of the air in the room." AI drug discovery investments are lifting biopharma funding totals overall, but women health companies are not yet capitalizing the way the rest of healthcare is.
So the failure of the traditional method here is not misogyny alone, and pretending it is makes the fix harder to see. The failure is that a squeezed market rewards the companies with the fastest, cheapest proof of value. Women health companies pitching slow, expensive, long-horizon science get squeezed hardest. The ones with quick, obvious traction, like diagnostics or testing services that reach market faster than a new medicine, keep moving.
The Cognitive Architecture of the Problem
Here is the part that connects to your kitchen table. What investors count as traction is shaped by what they think the product is for. For decades the addressable market in women health was defined narrowly: contraception, fertility, maternal complications. Real categories, but ones investors historically read as small and risky.
Scheffel says companies are now changing the pitch. The addressable market is bigger: conditions like depression, obesity or heart disease that affect women and men but impact women differently, disproportionately or uniquely. As she put it, founders do not come out and say they serve only women, because they are serving women and men. She called it "a marketing issue more than it is anything else."
The mental load sits exactly at this intersection. University of Bath research published in 2024 in the Journal of Marriage and Family found mothers carry 71 percent of household cognitive labor, and that share barely shrinks when mothers earn more or work more hours. Cognitive labor is depression risk, chronic stress, sleep disruption and time poverty rolled into one invisible workload. A market that only counts fertility clinics misses it entirely. A market that counts the conditions this workload drives sees tens of millions of households.
There is one more signal in the SVB report worth sitting with. A Pew Research Center poll cited in the report found women are less likely than men to believe AI can improve their healthcare. Skepticism is rational; women have watched health systems dismiss their symptoms for generations. Yet Scheffel points out that women health companies are sitting on troves of data on pregnancy and menopause, data that could surface treatments for conditions research has ignored. The architecture of the problem is a loop: trust gaps keep data thin, thin data keeps products shallow, shallow products keep trust low.
The AlphaMa Solution: Moving the Burden
The bright spots in the SVB report are the ones mothers should watch. Fourteen women health startups went public in 2025 after zero did in 2024. The report also counts 18 women health companies acquired in 2025. Unicorns like Flo Health, Midi Health and Maven keep emerging. Dealroom data suggests femtech startups raised 724 million dollars in 2025, with another 239 million in the first half of 2026. Capital F, one of the few all-female-led VC firms, closed a 17 million dollar debut fund in August 2026 to back what it calls the female economy. The money did not vanish. It moved toward companies that can prove, fast, that they change outcomes for women.
That is the standard AlphaMa was built to meet. The health system finally proved, in a JAMA Network Open study published August 25, 2026, that when somebody else does the scheduling, when the default flips from "call and book it yourself" to "it is already done," mothers are about twice as likely to get the care they need. AlphaMa is an AI agent built on that same principle: the burden of remembering, tracking, following up and planning belongs to software, not to you. Not another app you have to feed and manage. An agent that holds the load and hands you back the decision.
Funding will keep swinging. Resets will keep resetting. What mothers should demand from every company chasing this market is simple: stop building tools that give women one more job, and start building ones that take jobs away.
Sources
- Silicon Valley Bank report on women health venture funding, reported by BioPharma Dive, August 2026
- University of Bath, Journal of Marriage and Family, 2024, household cognitive labor
- Dealroom femtech funding data, 2025 and first half of 2026
- TechCrunch, Capital F closes 17 million dollar debut fund, August 2026
- JAMA Network Open, Facilitated Transitions to Postpartum Primary Care, August 25, 2026
